MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-03-2026
Teva Pharmaceutical Industries Limited ROE Ratio 2011-2026 | TEVA
Annual ROE Ratio Teva Pharmaceutical Industries Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.83 | -30.5 | -6.88 | -28.45 | 3.71 | -36.07 | -7.15 | -14.62 | -86.77 | 0.94 | 5.31 | 13.08 | 5.61 | 8.58 | 12.35 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.83 | -86.77 | -9.54 |
Quarterly ROE Ratio Teva Pharmaceutical Industries Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.67 | -12.19 | -18.16 | -20.65 | -25.28 | -14.98 | -12.55 | -12.9 | -3.77 | -11.08 | -8.53 | -6.57 | -2.2 | 5.33 | 6.82 | -39.11 | -39.71 | -39.8 | -40.51 | 0.62 | -5.7 | -7.14 | -27.55 | -26.72 | -22.99 | -14.62 | -61.45 | -56.6 | -89.8 | -93.7 | -26.08 | -28.33 | 6.9 | 4.1 | 4.56 | 3.84 | 5.34 | 4.76 | 8.47 | 11.72 | 12.56 | 10.12 | 13.31 | 12.79 | 7.51 | 3.86 | 3.52 | -0.02 | 5.88 | 7.18 | 11.18 | 15.53 | 14.17 | 9.74 | 4.01 | 2.43 | 3.3 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.53 | -93.7 | -9.87 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.88 | -2.07 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
-86.96 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
22.71 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 102.06 | - | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.91 | 0.34 % | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
-41.09 | $ 0.79 | 1.28 % | $ 27.9 M | Israel |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.68 | -2.33 % | $ 112 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
529.06 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 1.06 | -2.75 % | $ 12.9 M | USA |